ImaRx files IPO, Adventrx drops offering

ImaRx Therapeutics has filed to raise up to $75 million in a public offering. ImaRx specializes in developing drugs for vascular conditions. The Tucson, AZ-based biotech recently acquired Abbokinase, an established blood clot dissolver.

- read the StreetInsider report

ALSO: San Diego-based Adventrx Pharmaceuticals, meanwhile, has given up on its attempt to go public, citing "adverse market conditions." Adventrx also announced it has been cleared by the FDA to start a Phase III trial of CoFactor for metastatic colorectal cancer. Report